Literature DB >> 30211498

Pembrolizumab plus Chemotherapy in Lung Cancer.

Manuel D Gil-Sierra1,2, Silvia Fenix-Caballero3, Emilio Alegre-del Rey3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30211498     DOI： 10.1056/NEJMc1808567

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

Review 1.  Clinical and pharmacoeconomic impact of subgroup analysis in onco-hematological patients.

Authors:  Manuel David Gil-Sierra; Maria Del Pilar Briceño-Casado; Marina Sánchez-Hidalgo
Journal:  Support Care Cancer       Date:  2022-01-13       Impact factor: 3.359

2.  Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.

Authors:  Da Hyun Kang; Sung Soo Jung; Min-Kyung Yeo; Da Hye Lee; Geon Yoo; Sang Yeon Cho; In-Jae Oh; Ju-Ock Kim; Hee Sun Park; Chaeuk Chung; Jeong Eun Lee
Journal:  BMC Cancer       Date:  2020-06-18       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.